AnalystsSteve BrozakSteve Brozak's Stock Forecasts
AnalystsSteve Brozak
Sectors:
Analyst Ranking
Top 26%
#1453 out of 5550 analysts
Average Return
+20.78%
Win Rate
35%6 out of 17
Risk vs Reward
Poor
Good
Steve Brozak's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +392.50% | $44.95 | $221.38 | 2025-06-23 - 2026-01-06 | Strong Buy |
Cidara Therapeutics IncCDTX | +193.34% | $75.47 | $221.38 | 2025-09-22 - 2026-01-06 | Strong Buy |
Cidara Therapeutics IncCDTX | +149.92% | $88.58 | $221.38 | 2025-09-24 - 2026-01-06 | Strong Buy |
Cidara Therapeutics IncCDTX | +99.87% | $110.76 | $221.38 | 2025-10-09 - 2026-01-06 | Strong Buy |
Omeros CorpOMER | +76.87% | $10.42 | $18.43 | 2025-10-15 - 2026-10-14 | Strong Buy |
Steve Brozak Analyst Color
Get additional color on Steve Brozak's coverage of popular stocks
Steve Brozak's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vogenx IncVOGX | 1 | Buy | $42.00 | +107.41% | Initiates Coverage On | 2 months ago |
Omeros CorpOMER | 2 | Strong Buy | $45.00 | N/A | Reiterates | a year ago |
Cidara Therapeutics IncCDTX | 5 | Strong Buy | $199.00 | N/A | Maintains | a year ago |
Celularity IncCELU | 2 | Buy | $6.00 | N/A | Upgrades | a year ago |
Marker Therapeutics IncMRKR | 1 | Strong Buy | $12.50 | N/A | Reiterates | 2 years ago |
Contrafect CorpCFRXQ | 2 | Strong Buy | $560.00 | N/A | Upgrades | 4 years ago |
Paratek Pharmaceuticals IncPRTK | 1 | Strong Buy | $11.00 | N/A | Upgrades | 5 years ago |
Redhill Biopharma LtdRDHL | 2 | Buy | $16,000.00 | N/A | Downgrades | 5 years ago |
Cohbar IncCWBR | 1 | Buy | $135.00 | N/A | Initiates Coverage On | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.